Sharemaestro Newsreel

AbbVie's Skyrizi and Rinvoq Launches Support Lengthy Patent Protection and a Wide Moat

AbbVie's key drugs Skyrizi and Rinvoq are providing strong support for the company's lengthy patent protection and wide economic moat. Despite biosimilar competition impacting Humira revenue in 2023, AbbVie returned to growth in 2024, demonstrating the resilience of its diversified portfolio. The company maintains …

AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia

AbbVie (ABBV) has received European Commission approval for its drug RINVOQ (upadacitinib) for new indications in the EU. RINVOQ is now approved as the first systemic treatment for non-segmental vitiligo and as a systemic option for severe alopecia areata in adults and adolescents. These …

Biogen Inc. stock underperforms Friday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 2.40% on Friday, closing at $202.95, despite an overall positive trading session for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains. This marks the second consecutive day of losses for …

Grifols, S.A. Revenue Breakdown – NASDAQ:GRFS

Grifols, S.A. generated 8.88 billion USD in revenue last year, with its Biopharma segment contributing the most at 7.32 billion USD, an increase from the previous year. The United States and Canada were the largest regional contributors, accounting for 4.80 billion USD. The article …

Amgen Finds No Material Impact From Cybersecurity Incident

Amgen has reported that a recent cybersecurity incident resulted in the exfiltration of proprietary data and patient health information. However, the company has concluded that this breach will not have a material impact on its operations. This statement comes amidst several recent news items …

Mira Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Mira Pharmaceuticals (MIRA) announced that it received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement. The company's stock has traded below $1.00 for 30 consecutive business days, and it now has 180 days until January 25, 2027, to regain …

Amgen discloses data breach, says patient information was stolen

Drugmaker Amgen announced a data breach affecting patient health information stored in third-party cloud systems. The company deemed the incident material on July 29th and has initiated its cybersecurity response plan, including engaging independent forensic experts for investigation.

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Pfizer offers an attractive 6.8% dividend yield and trades at 8.5x forward earnings, with a promising late-stage weight loss drug in its pipeline. Despite these positives, its stock has been stagnant due to recent negative revenue growth and upcoming patent expirations for key products …

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline

Johnson & Johnson (JNJ) shares are trading higher following significant biotech acquisitions aimed at expanding its oncology pipeline. The company is acquiring Firefly Bio Inc. for $1 billion and has partnered with Sail Biomedicines, with an option to buy it for $2.58 billion, to …

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi's new CEO, Belén Garijo, aims to strengthen the company's partnership with Regeneron, expanding their alliance and increasing transparency. This comes as Sanofi prepares for Dupixent's patent cliff by focusing on business development and M&A. Separately, Apnimed's IPO surpassed expectations, becoming the 15th "upsized" …

Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings

This article compares the Q1 FY2026 performance of Eli Lilly and Novo Nordisk, highlighting Lilly's significant revenue growth and raised guidance due to strong Mounjaro and Zepbound sales, contrasted with Novo Nordisk's adjusted sales decline and restructuring. While Lilly is in expansion mode with …

Grifols Reshapes Board and Committee Leadership After Director Resignation

Grifols SA has announced significant changes to its board and committee leadership following the resignation of independent director Iñigo Sánchez-Asiaín Mardones. Joanna Susan Le Couilliard has been appointed as an independent director and chair of the Audit Committee, while Montserrat Muñoz Abellana joins the …

Novo Nordisk Stock Drops After Drug Fails in Cardiovascular Trial

Novo Nordisk's stock dropped significantly after its experimental drug, ziltivekimab, failed to reduce the risk of major adverse cardiovascular events in a late-stage trial. The Danish drugmaker's shares fell nearly 8% in Denmark and its American depositary receipts were down more than 9% in …

Press Release: Organon Announces Quarterly Dividend

Organon (NYSE: OGN) has announced a quarterly dividend of $0.28 per share of common stock. The dividend is payable on September 12, 2024, to shareholders of record as of the close of business on August 21, 2024.

Johnson & Johnson agrees to $5.5B settlement to resolve ovarian cancer talc lawsuits

Johnson & Johnson has agreed to a $5.5 billion settlement to resolve approximately 70,000 lawsuits alleging its talcum powder products cause ovarian cancer. The settlement aims to resolve long-running litigation, although J&J maintains its products are safe and do not cause cancer. The agreement …

Johnson & Johnson and Firefly: Targeting KRAS-Driven Cancers

Johnson & Johnson has acquired Firefly Bio, a preclinical biotechnology company, to advance treatments for KRAS-driven cancers, which are notoriously difficult to treat. Firefly Bio's degrader antibody conjugate (DAC) technology aims to selectively deliver protein degraders to cancer cells, offering a new approach to …

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat

AbbVie (NYSE: ABBV) shares fell after the company trimmed its full-year earnings guidance, despite reporting strong second-quarter earnings and revenue beats. The guidance reduction is primarily attributed to the anticipated acquisition of Apogee Therapeutics, which is expected to negatively impact 2026 earnings, although underlying …

Amgen Stock Leads 3 Cardiovascular Pharma Picks After Novo Nordisk Trial Miss

Following Novo Nordisk's failed late-stage heart drug trial, attention has shifted to other pharmaceutical companies with strong cardiovascular pipelines. This article highlights Amgen (AMGN), Pfizer Limited (NSEI:PFIZER), and Sanofi (ENXTPA:SAN) as potential beneficiaries. Each company is analyzed for its existing cardiovascular portfolio, growth prospects, …

Organon declares $0.02 quarterly dividend per share

Organon & Co. (NYSE: OGN) has announced a quarterly dividend of $0.02 per share of common stock. This dividend is scheduled to be paid on September 10, 2026, to shareholders recorded by August 14, 2026. Organon is a healthcare company based in Jersey City, …

AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal

AbbVie beat second-quarter profit estimates due to strong immunology sales but announced a cut in its full-year adjusted earnings forecast by 14 cents per share. This reduction is attributed to the planned acquisition of Apogee Therapeutics for approximately $10.9 billion. The stock subsequently dropped …

Organon: Q2 Earnings Snapshot

Organon & Co. 2026: Revenue $1.56B, EPS $0.4— 10-Q Summary

Organon & Co. reported its 2026 quarterly results, showing a decline in revenue, net income, and diluted EPS compared to the prior-year quarter. Revenue was $1.56 billion, with a diluted EPS of $0.4. The company is in the process of being acquired by Sun …

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

This article analyzes Eli Lilly and Company (LLY) by reviewing its recent stock performance, earnings estimate revisions, revenue growth forecasts, last reported results, and valuation. It highlights that while the stock has seen a -4.9% return over the past month, analysts have adjusted earnings …

AbbVie shares fall on earnings miss and weak guidance

AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings that missed analyst profit expectations, despite revenue beating estimates. The pharmaceutical company's shares fell 4.7% premarket due to the earnings miss and a lower-than-expected full-year guidance, which includes impacts from a proposed acquisition and IPR&D expenses. Despite …

AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates

AbbVie slightly reduced its 2026 profit forecast due to its planned acquisition of Apogee Therapeutics, which is expected to cut full-year earnings by 4 cents per share. Despite this, the company exceeded second-quarter estimates with strong immunology drug sales from Skyrizi and Rinvoq, counteracting …

AbbVie Sales Beat Estimates as Botox Shows Signs of Revival

AbbVie Inc. exceeded Wall Street's second-quarter profit and sales expectations, driven by robust performance in its immunology and neuroscience divisions. The company's top-selling drugs, including the wrinkle-smoothing injection Botox, outperformed forecasts, with Botox sales showing improvement for the third consecutive quarter. Adjusted earnings also …

Biogen stock price target raised to $251 by H.C. Wainwright

H.C. Wainwright raised its price target on Biogen Inc. (NASDAQ:BIIB) to $251 from $237, maintaining a Buy rating, as the company prepares to release results from its lupus drug trials. The firm anticipates a low-to-high-teens SRI-4 separation in the upcoming Phase 3 TOPAZ studies. …

AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer

AstraZeneca announced that the European Commission has approved its antibody-drug conjugate, Datroway, developed with Daiichi Sankyo, for a second breast cancer indication in the EU. This approval means the intravenous infusion will be available in the 27 EU member states, expanding its use for …

Vestor Capital LLC Invests $3.26 Million in Amgen Inc. $AMGN

Vestor Capital LLC has invested $3.26 million in Amgen Inc. by purchasing 9,269 shares during the first quarter. Amgen reported strong quarterly earnings, beating estimates with $5.15 per share and a 5.8% increase in revenue. Despite mixed analyst sentiment and competition in the weight-loss …

6,407 Shares in Amgen Inc. $AMGN Bought by January Capital Advisors LLC

January Capital Advisors LLC has acquired a new position of 6,407 shares in Amgen Inc. (NASDAQ:AMGN), valued at approximately $2.25 million, making it their seventh-largest holding. Amgen recently reported strong quarterly earnings, beating analyst estimates with $5.15 EPS and revenue of $8.62 billion, and …

Janus Henderson Group PLC Sells 1,215,634 Shares of Amgen Inc. $AMGN

Janus Henderson Group PLC significantly reduced its stake in Amgen Inc. by selling 1,215,634 shares, decreasing its holdings by 52.3% in the first quarter. Despite this, other hedge funds increased their positions in Amgen, indicating mixed institutional sentiment. The article also highlights recent positive …

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Novo Nordisk's stock declined by 9% after its late-stage ZEUS trial for ziltivekimab, a drug targeting heart and kidney disease and inflammation, failed. The trial, involving 6,300 patients, aimed to reduce cardiovascular-related deaths, nonfatal heart attacks, and strokes. This setback adds to the company's …

Johnson & Johnson settlement: Does talcum powder really increase ovarian cancer risk?

Johnson & Johnson has agreed to a multi-billion dollar settlement over lawsuits alleging its talcum powder caused ovarian cancer due to asbestos contamination. Experts explain that while IARC classifies talc not containing asbestos as "probably carcinogenic," scientific consensus doesn't definitively link it to ovarian …

Bristol Myers Squibb (BMY) Earnings Beat And Higher Outlook Put Valuation Back In Focus

Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail

Novo Nordisk's ziltivekimab, an IL-6 antibody, failed to meet its primary endpoint in the Zeus phase 3 trial for chronic kidney disease, atherosclerotic cardiovascular disease, and inflammation. This setback significantly dampens the drug's prospects, which analysts had projected to generate blockbuster sales. The company …

Dividend Roundup: Wells Fargo, Merck, Citigroup, Carnival Corp, and more

This dividend roundup highlights recent activity including increased payouts from Wells Fargo and Union Pacific, and declarations from Merck and Marathon Petroleum. The article also anticipates upcoming dividend activity from companies like Citigroup.